Sulodexide, a standardized extractive glycosaminoglycan containing 80% “fast moving” heparin and 20% dermatan sulfate, decreased plasma D-dimer, a marker of intravascular coagulation, and fibrinogen levels in chronic peritoneal dialysis patients. Blood levels of von Willebrand factor, lipid, and high-sensitivity C-reactive protein were not significantly changed. No bleeding episodes were reported. These results suggest that sulodexide was effective in partially reversing the thrombogenic coagulation profile without increasing the risk of bleeding.
CoccheriS., ScondottoG., AgnelliG., PalazziniE., ZamboniV.Sulodexide in the treatment of intermittent claudication.Eur Heart J2002; 23: 1057–65.
2.
CospiteM., MilioG., FerraraF., SalanitriG.Double blind study of the pharmacological effects of sulodexide in patients with multiple atherosclerotic vascular disease.Eur Rev Med Pharmacol Sci1985; 7: 97–105.
3.
GhoshA.K., HirasawaN., LeeY.S., KimY.S., ShinK.H., RyuN.Inhibition by acharan sulphate of angiogenesis in experimental inflammation models.Br J Pharmacol2002; 137: 441–8.
4.
DedovI., ShestakovaM., VorontzovA., PalazziniE.A randomized, controlled study of sulodexide for the treatment of diabetic nephropathy.Nephrol Dial Transplant1997; 12: 2295–300.
5.
GambaroG., KinalskaI., OksaA., Pont'uchP., HertlovaM., OlsovskyJ.Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type I and type 2 diabetic patients: The Di.N.A.S. Randomized Trial.J Am Soc Nephrol2002; 13: 1615–25.
6.
FracassoA., BaggioB., MasieroM., BonfanteL., BazzatoG., FerianiM.Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients.Perit Dial Int2003; 23: 595–9.
7.
KimS.B., ChangJ.W., LeeS.K., ParkJ.S.Acute systemic inflammation is associated with an increase of peritoneal solute transport rate in chronic peritoneal dialysis patients.Perit Dial Int2004; 24: 597–600.
8.
CavalloF., PesceD., CattaneoA., ForneroA., BenvenutoA.The efficacy of sulodexide treatment for ischemic cardiopathies with chronic atherosclerotic vasculopathies [in Italian].Alim Nutr Metab1986; 7: 103–11.
9.
CastelluccioA., BolognaE.Effect of sulodexide on blood viscosity in patients with peripheral vascular disease.Curr Med Res Opin1991; 12: 325–31.
10.
SpinarJ., NovotnyJ., MayerJ., VitovecJ., SpinarovaL.Hemocoagulation and hemorrheology in heart failure and the possible effects of glycosaminoglycans.Vnitr Lek1995; 41: 3–7.
11.
PalazziniE., VerardiS.Effect of a naturally occurring mucopolysaccharide, glucuronil-glycosaminoglycan sulfate, on coagulative profile and lipemic parameters in patients under chronic hemodialytic treatment.Current Therapeutic Research1981; 29: 678–84.
12.
ChangJ.W., YangW.S., MinW.K., LeeS.K., ParkJ.S., ChiH.S.Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.Am J Kidney Dis2002; 39: 1213–17.
13.
BrownerW.S., BlackD., NewmanT.B., HulleyS.B.Estimating sample size and power. In: HulleyS.B., CummingS.R., eds. Designing Clinical Research.Baltimore: Williams & Wilkins; 1988: 139–50.
14.
CondorelliM., ChiarielloM., DagiantiA., PencoM., Dalla VoltaS., PengoV.IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction.J Am Coll Cardiol1994; 23: 27–34.
15.
HarenbergJ.Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide.Med Res Rev1998; 18: 1–20.
